Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small mole…
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Cullinan Oncology, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -2.040 | - | 4 | - | -84 | - | 2 | - | 2 | - | 4 |
| 2021 | -1.1700 | -1.278 | 0 | 18 | -50 | -53 | -60 | 11 | -60 | 11 | 17 | 20 |
| 2023 | 2.4600 | -4.086 | 0 | 0 | 111 | -169 | 151 | 0 | -132 | 0 | 40 | 0 |
| 2024 | -3.6900 | -3.038 | 0 | 1 | -153 | -130 | -190 | 1 | -191 | 1 | 42 | 1 |
| 2025 | - | -3.165 | - | 6 | - | -139 | - | 4 | - | 4 | - | 7 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |